CompletedNot Applicable

Right Ventricular Outflow Tract Study

China380 participantsStarted 2011-03

Plain-language summary

This is a prospective, randomized, double blinded, multi-center, controlled study to evaluate the clinical impact at 18 months after DDD implantation of alternative pacing site (RVOTs and RVA) and the different conduction path (RVOTs and AV node) on cardiac dysfunction prevention.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with only sinus-node dysfunction and meet pacing indication * Patients with LVEF≥60% and with ventricular synchrony. * Patients signed the written informed consent for the study * Patients can endure the required follow up Exclusion Criteria: * Patients with atrial fibrillation * Patients with atrial-ventricular block * Patients with LBBB * Patients with significant valvular disease * Patients with severe hematopathy or severe renal inadequacy * Patients with life expectancy \< 1.5 year * Patients who are in the period of pregnant or lactation * Patients who are younger than 18 years old * Patients who are ongoing other devices or agents study

What they're measuring

Left ventricular ejection fraction (LVEF)

Timeframe: 18 months

Trial details

NCT IDNCT01294839

SponsorAbbott Medical Devices

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2016-06

View on ClinicalTrials.gov More Sinus-node Dysfunction trials